Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone

Shaoxiong Chen, Karen Fritchie, Shi Wei, Naser Ali, Kendra Curless, Tiansheng Shen, Anna T. Brini, Farida Latif, Vaiyapuri Sumathi, Gene P. Siegal, Liang Cheng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Histologically, it is nearly impossible to distinguish the dedifferentiated component of dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma (UPS) of bone when the low-grade cartilaginous component is absent. Previous studies have revealed that isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are present in a significant number of cartilaginous tumors including most conventional chondrosarcomas and dedifferentiated chondrosarcomas. These mutations have not been studied in UPSs of bone. We sought to investigate whether an IDH1 or IDH2 mutation signature could be used as a clinically diagnostic marker for the distinction of dedifferentiated component of chondrosarcoma from UPS of bone. Sixty-eight bone tumor cases, including 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPSs of bone, were collected for IDH1/2 mutation analysis either using the Qiagen IDH1/2 RGQ PCR Kit or using whole-exome sequencing. IDH1/2 mutations were detected in 87% (20/23) of dedifferentiated chondrosarcomas and 30% (6/20) of conventional chondrosarcomas. No mutations were detected in the IDH1/2 codon 132 or codon 172 among 14 UPSs of bone. Identification of IDH1 or IDH2 mutations supports the diagnosis of dedifferentiated chondrosarcoma rather than UPS of bone while also providing some insight into the pathogenesis of these 2 lesions.

Original languageEnglish (US)
Pages (from-to)239-246
Number of pages8
JournalHuman Pathology
Volume65
DOIs
StatePublished - Jul 1 2017

Fingerprint

Isocitrate Dehydrogenase
Chondrosarcoma
Sarcoma
Bone and Bones
Mutation
Codon
Exome
Neoplasms
Polymerase Chain Reaction

Keywords

  • Dedifferentiated chondrosarcoma
  • IDH1
  • IDH2
  • Undifferentiated pleomorphic sarcoma (UPS) of bone

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. / Chen, Shaoxiong; Fritchie, Karen; Wei, Shi; Ali, Naser; Curless, Kendra; Shen, Tiansheng; Brini, Anna T.; Latif, Farida; Sumathi, Vaiyapuri; Siegal, Gene P.; Cheng, Liang.

In: Human Pathology, Vol. 65, 01.07.2017, p. 239-246.

Research output: Contribution to journalArticle

Chen, Shaoxiong ; Fritchie, Karen ; Wei, Shi ; Ali, Naser ; Curless, Kendra ; Shen, Tiansheng ; Brini, Anna T. ; Latif, Farida ; Sumathi, Vaiyapuri ; Siegal, Gene P. ; Cheng, Liang. / Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. In: Human Pathology. 2017 ; Vol. 65. pp. 239-246.
@article{ca4c7b445b5741d28c5e63a9582d8d8d,
title = "Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone",
abstract = "Histologically, it is nearly impossible to distinguish the dedifferentiated component of dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma (UPS) of bone when the low-grade cartilaginous component is absent. Previous studies have revealed that isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are present in a significant number of cartilaginous tumors including most conventional chondrosarcomas and dedifferentiated chondrosarcomas. These mutations have not been studied in UPSs of bone. We sought to investigate whether an IDH1 or IDH2 mutation signature could be used as a clinically diagnostic marker for the distinction of dedifferentiated component of chondrosarcoma from UPS of bone. Sixty-eight bone tumor cases, including 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPSs of bone, were collected for IDH1/2 mutation analysis either using the Qiagen IDH1/2 RGQ PCR Kit or using whole-exome sequencing. IDH1/2 mutations were detected in 87{\%} (20/23) of dedifferentiated chondrosarcomas and 30{\%} (6/20) of conventional chondrosarcomas. No mutations were detected in the IDH1/2 codon 132 or codon 172 among 14 UPSs of bone. Identification of IDH1 or IDH2 mutations supports the diagnosis of dedifferentiated chondrosarcoma rather than UPS of bone while also providing some insight into the pathogenesis of these 2 lesions.",
keywords = "Dedifferentiated chondrosarcoma, IDH1, IDH2, Undifferentiated pleomorphic sarcoma (UPS) of bone",
author = "Shaoxiong Chen and Karen Fritchie and Shi Wei and Naser Ali and Kendra Curless and Tiansheng Shen and Brini, {Anna T.} and Farida Latif and Vaiyapuri Sumathi and Siegal, {Gene P.} and Liang Cheng",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.humpath.2017.05.015",
language = "English (US)",
volume = "65",
pages = "239--246",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone

AU - Chen, Shaoxiong

AU - Fritchie, Karen

AU - Wei, Shi

AU - Ali, Naser

AU - Curless, Kendra

AU - Shen, Tiansheng

AU - Brini, Anna T.

AU - Latif, Farida

AU - Sumathi, Vaiyapuri

AU - Siegal, Gene P.

AU - Cheng, Liang

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Histologically, it is nearly impossible to distinguish the dedifferentiated component of dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma (UPS) of bone when the low-grade cartilaginous component is absent. Previous studies have revealed that isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are present in a significant number of cartilaginous tumors including most conventional chondrosarcomas and dedifferentiated chondrosarcomas. These mutations have not been studied in UPSs of bone. We sought to investigate whether an IDH1 or IDH2 mutation signature could be used as a clinically diagnostic marker for the distinction of dedifferentiated component of chondrosarcoma from UPS of bone. Sixty-eight bone tumor cases, including 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPSs of bone, were collected for IDH1/2 mutation analysis either using the Qiagen IDH1/2 RGQ PCR Kit or using whole-exome sequencing. IDH1/2 mutations were detected in 87% (20/23) of dedifferentiated chondrosarcomas and 30% (6/20) of conventional chondrosarcomas. No mutations were detected in the IDH1/2 codon 132 or codon 172 among 14 UPSs of bone. Identification of IDH1 or IDH2 mutations supports the diagnosis of dedifferentiated chondrosarcoma rather than UPS of bone while also providing some insight into the pathogenesis of these 2 lesions.

AB - Histologically, it is nearly impossible to distinguish the dedifferentiated component of dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma (UPS) of bone when the low-grade cartilaginous component is absent. Previous studies have revealed that isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are present in a significant number of cartilaginous tumors including most conventional chondrosarcomas and dedifferentiated chondrosarcomas. These mutations have not been studied in UPSs of bone. We sought to investigate whether an IDH1 or IDH2 mutation signature could be used as a clinically diagnostic marker for the distinction of dedifferentiated component of chondrosarcoma from UPS of bone. Sixty-eight bone tumor cases, including 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPSs of bone, were collected for IDH1/2 mutation analysis either using the Qiagen IDH1/2 RGQ PCR Kit or using whole-exome sequencing. IDH1/2 mutations were detected in 87% (20/23) of dedifferentiated chondrosarcomas and 30% (6/20) of conventional chondrosarcomas. No mutations were detected in the IDH1/2 codon 132 or codon 172 among 14 UPSs of bone. Identification of IDH1 or IDH2 mutations supports the diagnosis of dedifferentiated chondrosarcoma rather than UPS of bone while also providing some insight into the pathogenesis of these 2 lesions.

KW - Dedifferentiated chondrosarcoma

KW - IDH1

KW - IDH2

KW - Undifferentiated pleomorphic sarcoma (UPS) of bone

UR - http://www.scopus.com/inward/record.url?scp=85022229593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022229593&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2017.05.015

DO - 10.1016/j.humpath.2017.05.015

M3 - Article

VL - 65

SP - 239

EP - 246

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -